Perjeta 420 mg Concentrate solution for infusion
PDF Leaflet Revision Date: 18 October 2022
Clinical Summary
Quick overview from the medicine insert
Indication
HER2-positive metastatic or locally recurrent unresectable breast cancer.
Dosage (summary)
Initial: 840 mg IV infusion over 60 mins; Maintenance: 420 mg IV every 3 weeks over 30-60 mins.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; avoid breastfeeding during treatment.
Key Drug Interactions
- No significant interactions with trastuzumab or docetaxel
Contraindications
- Hypersensitivity to pertuzumab or excipients
Common side effects
- Diarrhoea
- Alopecia
- Nausea
- Fatigue
- Neutropenia
- Vomiting
Counselling Points
- Monitor for infusion reactions
- Use effective contraception during treatment
- Do not breastfeed while on treatment
Serious warnings
- Infusion-related reactions
- Hypersensitivity reactions
- Left ventricular dysfunction
Important Disclaimer
The Perjeta 420 mg Concentrate solution for infusion professional information leaflet below is the property of Roche Products and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
